Showing 61 - 64 results of 64 for search '"K–12"', query time: 0.05s Refine Results
  1. 61

    Exploring MAP3K genes in gastric cancer: biomarkers, tumor microenvironment dynamics, and chemotherapy resistance by Senhui Wei, Ying Li, Jing Zhou, Yongming Xia

    Published 2025-02-01
    “…Results Utilizing RT-qPCR analysis, we observed significant up-regulation of MAP3K1, MAP3K4, MAP3K5, MAP3K6, MAP3K7, MAP3K8, MAP3K9, and MAP3K10 in GC cell lines, while MAP3K2, MAP3K3, MAP3K11, MAP3K12, MAP3K13, MAP3K14, and MAP3K15 exhibited down-regulation. …”
    Get full text
    Article
  2. 62

    Room temperature self-assembly and nonenzymatic electrochemical sensing performance of transition metal-embedded wheel-shaped tungstophosphates by Wen-Da Liu, Hao-Tian Zhu, Xue Zhang, Fang Su, Xiao-Jing Sang, Xiao-Lan Zhang, Lan-Cui Zhang

    Published 2025-03-01
    “…Under heat-free conditions, three wheel-shaped [P8W48O184]40− ({P8W48})-based polyoxometalates (POMs) were controllably synthesized via the reaction of a hexavacant Dawson-type tungstophosphate, K12[H2P2W12O48]·24H2O (K-{P2W12}), with simple transition metal (TM) (TM = Mn, Co, and Ni) salts in room temperature aqueous solutions. …”
    Get full text
    Article
  3. 63

    Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies by Francesco Di Pierro, Francesco Di Pierro, Francesco Di Pierro, Fazle Rabbani, Meherullah Tareen, Roohi Nigar, Amjad Khan, Nicola Zerbinati, Maria L. Tanda, Massimiliano Cazzaniga, Alexander Bertuccioli, Alexander Bertuccioli, Paolo Falasca, Gabriele Damiani, Nicola Villanova

    Published 2025-02-01
    “…Cohort 1 consisted of 164 healthy participants (87 QP-treated, 77 probiotic Streptococcus salivarius (S. salivarius) K12-treated) who were monitored for 90 days. Cohort 2 included 22 mildly hyperuricemic adults with metabolic disorders receiving QP, while Cohort 3 comprised 64 obese adults with hypercholesterolemia, further divided into moderately hyperuricemic QP-treated group (n = 20), a moderately hyperuricemic Berberine Phytosome™ and monacolins (BM)-treated group (n = 22), and a normouricemic BM-treated group (n = 22). …”
    Get full text
    Article
  4. 64